Forget trading. Call me for multibagger stocks. Two research reports monthly. I have a scrip which will be 10 bagger in my portfolio. Contact on gsk1595@rediffmail.com or 9765889870.
Dear, I have applied for 5 Lots but not allotted any shares & not still received refund of same, can you tel me were to complaints any contact no. / mail Id
If you have not been allotted, don''t worry.. you will get below IPO price over a period of time.. contract research business will always have up and down... Not a great stock for long term.. Discl: don''t hold
THE RETAIL PORTION OF THE IPO WAS OVERSUBSCRIBED TO ONLY 4.7 TIME, BUT THE COMPANY HAS NOT ALLOTTED SHARES TO THOSE INVESTORS WHO APPLY MORE THAN 6 TIME OF THE MINIMUM LOT OF SHARES I.E. 60 SHARE. I HAVE APPLY FOR 360 SHARES BUT NOT ALLOTTED ANY SHARE. WAS INFORMED BY THE KARVY OFFICE THAT RETAIL INVESTORS WERE ALLOTTED SHARES IN THE RATIO OF 16:43 AND THAT IS THE REASON FOR NOT ALLOTMENT. NOW I OBSERVED THAT THE COMPANIES ALLOTTED ONLY ONE LOT OF SHARES TO RETAIL INVESTORS IN CASE OF OVER SUBSCRIPTION.THEREFORE, NOW EVERY RETAIL INVESTOR SHOULD APPLY FOR ONLY ONE LOT OF SHARES AND DO NOT INVEST UPTO RS. 2,00,000/-.
I had applied for 780 shares of Syngene International Ltd through ICICIDIRECT.COM through at cut off price. Although the allotment is made on proportionate basis, I have not been allotted any shares. What could be the reason for this and what is the remedy left for me.
Pinkyji, the basis of allotment link on this website says allotment document for syngene not released yet. I''llb grateful if u can give me the exact basis of allotmentfor each category in syngene ipo. My email is jimishb at the rate gmail dot com
Basis of IPO stock allocation is published by the registrar of the issue in two weeks of IPO share bid closing date. Why is it not out for syngene yet?
1. Syngene International started operations in 1993 providing contract research in chemistry and biology. It now has discovery and development service offerings across small and large molecules, DNA molecules and antibody-drug conjugates.
2. Kiran Mazumdar-Shaw is the founder of Syngene. The company was first established as a private limited company in 1993 and became a public limited entity in 2007. In 2002, 99.9% of its equity shares were transferred to Biocon Ltd, making it a subsidiary of the company.
3. Silver Leaf Oak Advisors has held a 10% stake in the company since 2014.
4. Bristol Myers Squibb, Abbott Laboratories (Singapore) Pte. Ltd and Baxter International Inc. are three of its major clients. It also has smaller clients such as Achillion Pharmaceuticals Inc., Aquinox Pharmaceuticals Inc. and Saniona AB. The total count of clients as of March this year was 221, only 5% of whom are based in India.
5. Seventy percent of its revenue comes from the top 10 clients. Bristol Myers Squibb alone contributes 30%. These clients have long-term contracts.
6. It has 400 scientists working exclusively for Bristol Myers Squibb. It also has 150 scientists for Baxter and 30 scientists for Abbott.
7. Syngene has 900,000 sq. ft of work space in Bengaluru and is also in the process of setting up a 200,000 sq. ft research centre and a manufacturing facility.
8. The contract research provider has 2,685 employees, of whom 2,122 are scientists, with an average age of less than 28 years. 24% of revenue, or Rs.200 crore, went toward employee benefits in the year ended March.
9. Syngene has so far developed monoclonal antibodies, glycoproteins, complex proteins, conjugated proteins in E. coli and Chinese hamster ovary cells.
10. Clinigene is the clinical trials subsidiary of Syngene, which accounts for less than 10% of its revenue.
IT WILL GIVE GOOD RETURN IN LONG TERM, WHEN WE ARE COMPARING IT WITH "SPARC" A SUN PHARMA SUBSIDIARY (LOSS MAKING), IT IS WORTH TO HOLD UP TO Rs. 400......
I had applied for 1 lot in the morning on the very first day. But not alloted. What is the reason??? On what basis they allot? Does the number of lots matter???
Please guide as I do not want to miss on upcoming Alkem IPO.
As per SEBI rules they will try to allot atleast one lot to each applicant. But if number of applications is more than number of lots available, they will do lottery.
This is not a real pharma stock, but only contract research service provider.. do not make case for long term investment... they have waited for more than 5 years and wanted good time to sell shows it is not so good for long term investment..